ProKyma is focused on developing its system to improve the detection of circulating tumour cells and monitoring of cell numbers as a indication of the patient's response to therapy.
Other areas that the dual force approach can be applied to are available to other parties under licence.
Examples include a module working with a flow cytometer to clean up leukocytes, washing away red cell debris or a "no moving parts" module to manipulate magnetic particles in clinical analysers.
For further details please contact:
Damian Bond, CEO
Chris Stanley, Chairman